Lite Strategy (LITS) Return on Capital Employed (2011 - 2026)
Lite Strategy (LITS) posted quarterly Return on Capital Employed of 83.7% for Q1 2026, up 7352.0% year-over-year from 1.12% in Q1 2025, and down 106.9% quarter-over-quarter from 40.45% in Q4 2025.
Lite Strategy (LITS) Return on Capital Employed (2011 - 2026) Analysis & Trends
Lite Strategy's Return on Capital Employed history runs 16 years deep, the most recent figure standing at 83.7% for Q1 2026.
- In Q1 2026, Return on Capital Employed rose 7352.0% year-over-year to 83.7%; the TTM figure through Mar 2026 stood at 83.7% (up 7352.0% YoY), while the FY2025 annual figure was 61.3%, down 8129.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 83.7%, down from 40.45% in the prior quarter.
- The five-year high for Return on Capital Employed was 35.85% in Q3 2023, with the low at 170.78% in Q4 2024.
- The 5-year median for Return on Capital Employed is 40.45% (2025), against an average of 49.83%.
- Peak annual rise in Return on Capital Employed reached 13507 bps in 2025, while the deepest fall reached 19160 bps in 2025.
- Lite Strategy's Return on Capital Employed stood at 35.39% in 2022, then soared by 155 bps to 19.4% in 2023, then plunged by 980 bps to 170.78% in 2024, then surged by 76 bps to 40.45% in 2025, then slumped by 107 bps to 83.7% in 2026.
- Business Quant data shows LITS's Return on Capital Employed at 83.7% in Q1 2026, 40.45% in Q4 2025, and 19.84% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.60 Bn | 130.75 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.93 Bn | 77.93 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 65.06 Bn | 59.88 Bn | 1.37 Bn | - |
| 4 | Moderna | 56.22 Bn | 51.08 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 42.03 Bn | 36.93 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.65 Bn | 28.34 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 27.70 Bn | 9.31 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.31 Bn | 26.48 Bn | - | 7.88% |
| 10 | Lite Strategy | 36.78 Mn | 29.24 Mn | - | -83.70% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -83.70% |
| Dec 31, 2025 | -40.45% |
| Sep 30, 2025 | -19.84% |
| Jun 30, 2025 | -96.02% |
| Mar 31, 2025 | -157.22% |
| Dec 31, 2024 | -170.78% |
| Sep 30, 2024 | -154.91% |
| Jun 30, 2024 | 30.32% |
| Mar 31, 2024 | 34.38% |
| Dec 31, 2023 | 19.40% |
| Sep 30, 2023 | 35.85% |
| Jun 30, 2023 | -34.31% |
| Mar 31, 2023 | -35.71% |
| Dec 31, 2022 | -35.39% |
| Sep 30, 2022 | -49.97% |
| Jun 30, 2022 | -46.68% |
| Mar 31, 2022 | -42.00% |
| Dec 31, 2021 | -40.88% |
| Sep 30, 2021 | -43.88% |
| Jun 30, 2021 | -37.79% |